We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current LILY34 market cap is 125.55B. The company's latest EPS is USD 5.5202 and P/E is 139.77.
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 6.96B | 8.31B | 9.5B | 9.35B | 8.77B |
Operating Income | 1.49B | 2.13B | -3.24B | 2.4B | 2.51B |
Net Income | 1.34B | 1.76B | -57.4M | 2.19B | 2.24B |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 22.32B | 24.56B | 28.32B | 28.54B | 34.12B |
Operating Income | 5.47B | 6.06B | 6.66B | 7.37B | 6.46B |
Net Income | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 53.16B | 54.81B | 57.92B | 64.01B | 63.94B |
Total Liabilities | 41.87B | 43.66B | 46.61B | 53.14B | 51.05B |
Total Equity | 11.29B | 11.15B | 11.31B | 10.86B | 12.9B |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 39.29B | 46.63B | 48.81B | 49.49B | 64.01B |
Total Liabilities | 36.59B | 40.81B | 39.65B | 38.71B | 53.14B |
Total Equity | 2.7B | 5.83B | 9.15B | 10.78B | 10.86B |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 1.73B | 2.36B | 4.55B | 4.24B | 1.17B |
Investing | -688.8M | -1.15B | -4.23B | -7.15B | -1.18B |
Financing | 412.3M | -621.1M | -49.1M | 3.5B | -311.3M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 4.84B | 6.5B | 7.26B | 7.08B | 4.24B |
Investing | -8.08B | -2.26B | -2.76B | -3.26B | -7.15B |
Financing | -2.32B | -3.14B | -4.13B | -5.41B | 3.5B |
Market Cap | 125.55B |
Price to Earnings Ratio | 139.77 |
Price to Sales Ratio | 21.46 |
Price to Cash Ratio | 259.86 |
Price to Book Ratio | 67.42 |
Dividend Yield | - |
Shares Outstanding | 949.31M |
Average Volume (1 week) | 21.45k |
Average Volume (1 Month) | 8.68k |
52 Week Change | 82.01% |
52 Week High | 137.15 |
52 Week Low | 69.45 |
Spread (Intraday) | 4.92 (3.65%) |
Company Name | Lilly Drn |
Address |
334 north senate avenue indianapolis, indiana 46204 |
Website | https://www.lilly.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions